Compass Therapeutics (CMPX) News Today $2.02 -0.06 (-2.66%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Compass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at GuggenheimGuggenheim restated a "buy" rating on shares of Compass Therapeutics in a research report on Tuesday.April 24 at 9:47 AM | marketbeat.comCompass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at GuggenheimApril 24 at 2:33 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Compass Therapeutics (NASDAQ:CMPX)HC Wainwright reiterated a "buy" rating and issued a $24.00 target price on shares of Compass Therapeutics in a report on Monday.April 23 at 2:15 PM | marketbeat.comCompass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract CancerApril 23 at 12:15 PM | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and UnitedHealth (UNH)April 23 at 12:15 PM | markets.businessinsider.comCompass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Monday.April 23 at 8:39 AM | marketbeat.comRock Springs Capital Management LP Acquires 150,336 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)Rock Springs Capital Management LP grew its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,779,575 shares of the company's stock after buying an additional 150,336 shareApril 23 at 6:56 AM | marketbeat.comCompass Therapeutics announces first patient dosed in IST evaluating tovecimigApril 22 at 8:48 AM | markets.businessinsider.comCompass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract CancerApril 21 at 8:00 AM | globenewswire.comShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Increases By 43.6%Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 6,620,000 shares, an increase of 43.6% from the March 15th total of 4,610,000 shares. Approximately 8.2% of the company's shares are sold short. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is presently 3.1 days.April 20, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Director Carl L. Gordon Sells 3,571,428 SharesApril 12, 2025 | insidertrades.comJonathan Anderman Purchases 20,000 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) StockCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.April 10, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Insider Jonathan Anderman Acquires 20,000 SharesApril 9, 2025 | insidertrades.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright upped their price target on shares of Compass Therapeutics from $10.00 to $24.00 and gave the stock a "buy" rating in a report on Friday.April 6, 2025 | marketbeat.comQ3 EPS Estimates for Compass Therapeutics Cut by WedbushCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities research analysts at Wedbush lowered their Q3 2025 earnings estimates for shares of Compass Therapeutics in a report released on Tuesday, April 1st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings peApril 6, 2025 | marketbeat.comQ2 Earnings Estimate for CMPX Issued By Leerink PartnrsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Leerink Partnrs decreased their Q2 2025 EPS estimates for Compass Therapeutics in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst A. Berens now expects that the company will earn ($0.17) per sharApril 6, 2025 | marketbeat.comWedbush Reduces Earnings Estimates for Compass TherapeuticsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities research analysts at Wedbush cut their FY2028 EPS estimates for shares of Compass Therapeutics in a report released on Tuesday, April 1st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $1.17 per sApril 5, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink PartnrsLeerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday.April 5, 2025 | marketbeat.comCompass Therapeutics price target raised to $24 from $10 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comGuggenheim Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)Guggenheim reissued a "buy" rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday.April 4, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Rating Increased to Outperform at Leerink PartnersLeerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $4.00 to $6.00 in a research report on Wednesday.April 4, 2025 | marketbeat.comCompass Therapeutics Reports Positive Phase 2/3 Trial Results For TovecimigApril 3, 2025 | nasdaq.comCompass Therapeutics (NASDAQ:CMPX) Receives Outperform Rating from WedbushWedbush restated an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday.April 3, 2025 | marketbeat.comLeerink Partners Upgrades Compass Therapeutics (CMPX)April 3, 2025 | msn.comCompass Therapeutics (CMPX) Receives a Buy from GuggenheimApril 3, 2025 | markets.businessinsider.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and sApril 3, 2025 | marketbeat.comCompass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology ForumApril 2, 2025 | globenewswire.comCompass Therapeutics says tovecimig meets primary endpoint in Phase 2/3 studyApril 2, 2025 | markets.businessinsider.comInvestors Buy Large Volume of Compass Therapeutics Put Options (NASDAQ:CMPX)Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw unusually large options trading on Tuesday. Stock traders acquired 22,702 put options on the company. This is an increase of approximately 797% compared to the average volume of 2,532 put options.April 2, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 24.6% in MarchCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 4,610,000 shares, a growth of 24.6% from the February 28th total of 3,700,000 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is currently 3.2 days. Currently, 5.7% of the company's shares are sold short.April 2, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday.April 2, 2025 | marketbeat.comCompass Therapeutics posts clinical trial win for biliary tract cancer therapyApril 1, 2025 | msn.comTovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract CancerApril 1, 2025 | globenewswire.comCompass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract CancerMarch 31, 2025 | globenewswire.comWith 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interestMarch 18, 2025 | finance.yahoo.comCompass Therapeutics (CMPX) Projected to Post Earnings on ThursdayCompass Therapeutics (NASDAQ:CMPX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy ratiMarch 8, 2025 | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest UpdateCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 3,530,000 shares, a growth of 28.4% from the January 31st total of 2,750,000 shares. Currently, 4.4% of the shares of the company are sold short. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is presently 2.7 days.March 5, 2025 | marketbeat.comResearch Analysts Issue Forecasts for CMPX Q1 EarningsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Compass Therapeutics in a report released on Thursday, February 27th. HC Wainwright analyst J. Pantginis anticipates that the company will poMarch 3, 2025 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSCompass Therapeutics (NASDAQ:CMPX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01).February 28, 2025 | marketbeat.comCompass Therapeutics shares rise on pipeline progressFebruary 28, 2025 | za.investing.comCompass Therapeutics reports Q4 EPS (11c), consensus (9c)February 28, 2025 | markets.businessinsider.comCompass Therapeutics sees cash runway into 1Q27February 28, 2025 | markets.businessinsider.comCompass Therapeutics Reports 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | globenewswire.comCompass Therapeutics' (CMPX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.comGuggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy RecommendationFebruary 25, 2025 | msn.comCompass Therapeutics initiated with a Buy at GuggenheimFebruary 24, 2025 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated at GuggenheimGuggenheim initiated coverage on shares of Compass Therapeutics in a research note on Monday. They set a "buy" rating and a $12.00 price objective on the stock.February 24, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight RecommendationFebruary 20, 2025 | msn.comPiper Sandler Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday. They issued an "overweight" rating and a $12.00 price target for the company.February 20, 2025 | marketbeat.com Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Media Mentions By Week CMPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.450.72▲Average Medical News Sentiment CMPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼122▲CMPX Articles Average Week Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies WVE News ETNB News COLL News MLYS News NTLA News SYRE News ZYME News RCUS News NRIX News CMRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMPX Stock Free CMPX Stock Alerts